A liquid painted onto a child's cavity in a few seconds, with no drill, no injection and no sedation, stopped decay in more than half of the treated baby teeth in a U.S. clinical trial of 830 children under age 6.
The results, published in JAMA Pediatrics on July 27, come from a Phase III trial led by the University of Michigan and funded with more than $12 million from the National Institute of Dental and Craniofacial Research. It compared 38% silver diamine fluoride against placebo in children with severe early childhood caries, applied at six-month intervals.
For a parent, the practical appeal is obvious. Tooth decay is the most common chronic disease of childhood, affecting more than 40% of U.S. children, and the standard route for a small child with multiple cavities often runs through an operating room and general anesthesia.
What Arresting a Cavity Actually Means
This is the part most coverage will skip, and it changes what a parent should expect.
Arresting a cavity is not repairing it. A filling removes the decayed portion of the tooth and replaces it with material, restoring the tooth's shape. Silver diamine fluoride does neither. It halts the bacterial process driving the decay, leaving the cavity in place but inactive. The hole does not fill in.
The trial's primary outcome reflected that distinction: whether active cavitated dentin lesions became inactive, not whether teeth were restored.
There is also a visible tradeoff, and it is permanent. The silver darkens the decayed portion of the tooth, usually to black. Margherita Fontana, professor of dentistry at the University of Michigan School of Dentistry and the study's lead investigator, described the cosmetic effect as the treatment's primary drawback.
For a back molar on a baby tooth that will fall out anyway, many families accept the staining readily. For a front tooth, some do not. That is a reasonable conversation to have with a dentist rather than a question with one correct answer.
Fontana said in the University of Michigan announcement that "This is a very effective and safe treatment," and that reapplying it every few months may be all some children need until the baby tooth is lost naturally.
MedicalDaily Evidence Check
This is a randomized, placebo-controlled Phase III trial, which is the strongest design category in this field, and it is the reason this result carries more weight than the dental research that circulates on social feeds.
The trial enrolled 830 children younger than 6 with severe early childhood caries, recruited through dental offices, pediatric medical practices, and Head Start and Early Head Start programs in Michigan, New York and Iowa. It began in 2018 and continued through the pandemic. Investigators came from the University of Michigan, New York University, the University of Iowa, and Indiana University.
What it found: 38% silver diamine fluoride applied every six months arrested decay in more than half of affected primary teeth, compared with placebo.
What it did not establish: that the treatment restores teeth, that it works equally well on permanent teeth, or that it eliminates the need for dental care. The reported headline figure, more than half of treated teeth, also means a substantial share of lesions were not arrested. This is not a cure, and children who receive it still need a dental home and follow-up.
Readers should know the exact arrest percentage, the full follow-up duration, and the confidence intervals were not available in the materials released alongside publication, and editors should confirm those against the full text before treating any specific percentage as final.
Two disclosures matter. The product tested, Advantage Arrest 38% SDF, was supplied by its manufacturer, Elevate Oral Care. And the trial was explicitly designed to generate the data a manufacturer needs to file a cavity treatment application with the FDA. Neither fact invalidates the result, and the federal funding and independent academic sites are meaningful counterweights, but both belong in view.
Where This Sits in U.S. Regulation Right Now
Silver diamine fluoride is already in American dental offices, which surprises many parents. The FDA cleared it in 2014 as a medical device for tooth sensitivity, and dentists have used it off-label for cavities since. Dentists in other countries have used it for decades.
What has been missing is large U.S. trial evidence for efficacy and safety in treating cavities, which is what FDA approval as a drug for that purpose would require. This trial was built to fill that gap.
Approval has not happened. Amr Moursi, professor of pediatric dentistry at New York University College of Dentistry and a co-principal investigator, said the findings support approval and that "Removing SDF from off-label status would be an important innovation," pointing to potential effects on insurer payment and product consistency.
Until that happens, coverage remains uneven. Many state Medicaid programs and some private plans do pay for SDF application, often under specific procedure codes and with limits on frequency, but this varies by state and plan. Families should ask the dental office directly what it bills and what their plan covers, rather than assuming.
Who This Could Help Most
The children with the most to gain are those for whom conventional treatment is hardest to obtain or tolerate: very young children with multiple cavities, children who would otherwise need sedation or general anesthesia, and families far from a pediatric dentist or facing long waits.
Fontana noted the same logic may extend to older adults, people with developmental or physical disabilities, and patients with severe dental anxiety, for whom sitting through restorative work is difficult. For adults, she said, it may serve as a longer-term measure or as a bridge until restorative treatment becomes affordable or practical.
There is also a timing argument specific to young children. Most see a pediatrician years before they ever see a dentist, and a treatment simple enough to apply in a medical office could reach cavities earlier, before pain, infection or surgery.
What no parent should take from this is that decay can be ignored. Untreated cavities cause pain, infection, trouble eating and sleeping, missed school and repeat medical visits. Arresting a lesion is a way to manage decay, not a reason to skip dental care.
What Happens Next
The next milestone is regulatory. The trial data were assembled to support a dental caries drug application to the FDA, and no application decision has been announced. Whether the agency approves SDF for this use, and on what terms, will determine how widely it spreads into medical as well as dental settings.
For parents, the useful step now is a conversation, not a request for a specific product. Ask a dentist whether any of your child's cavities are candidates for arrest rather than restoration, what the staining will look like on the specific teeth involved, how often reapplication would be needed, and what the alternative would involve. Anyone whose child has facial swelling, fever or dental pain that wakes them at night should seek care promptly rather than waiting for a routine appointment.
The bottom line: a placebo-controlled U.S. trial in 830 young children found that 38% silver diamine fluoride, applied twice a year, arrested decay in more than half of treated baby teeth. The children most likely to benefit are those facing sedation or long waits for restorative care. The reasonable step is asking a dentist whether it fits your child's specific cavities. The central uncertainty is whether the FDA will approve it for this use.
Frequently Asked Questions
What did the trial find? That 38% silver diamine fluoride, applied at six-month intervals, arrested decay in more than half of affected baby teeth among 830 U.S. children under 6 with severe early childhood caries, compared with placebo.
Does this fix the cavity? No. It halts the decay process but does not restore the tooth. The hole remains, inactive. A filling replaces lost tooth structure; this does not.
Will it stain my child's teeth? Yes, permanently. The silver darkens the decayed area, usually to black. This is the treatment's main drawback and the most common reason families decline it for front teeth.
Is it FDA approved for cavities? No. It was cleared in 2014 as a device for tooth sensitivity and is used off-label for cavities. This trial was designed to support an application for approval as a cavity treatment.
Can I get it now? Many dentists already offer it. Ask whether your child's specific cavities are suitable, and ask the office about billing, since coverage varies by state and plan.
Is it safe? The investigators described it as safe in this trial, including in very young children. Discuss any silver sensitivity, mouth ulcers, or other oral conditions with the dentist first.
Does my child still need dental care? Yes. Arresting decay is not a substitute for a dental home, follow-up visits, or treatment of infection.
